3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Completed
3
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Plasma cell
3
Conditions
Breast Neoplasms
91
Carcinoma, Non-Small-Cell Lung
53
Lung Neoplasms
22
Hodgkin Disease
15
Recurrence
11
Lymphoma
10
Neoplasm Metastasis
9
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasms
6
Sarcoma
4
Rhabdomyosarcoma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Adenocarcinoma of Lung
4
Multiple Myeloma
3
Mesothelioma, Malignant
3
Mesothelioma
3
Breast Neoplasms, Male
3
Uterine Cervical Neoplasms
2
Ovarian Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lymphoma, Large-Cell, Anaplastic
2
HER2-negative Breast Cancer
2
Fallopian Tube Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Colonic Neoplasms
2
Brain Neoplasms
2
Advanced Breast Cancer
2
Interventions
Dexamethasone
338
Bortezomib
188
Lenalidomide
186
Cyclophosphamide
166
Melphalan
124
Calcium Dobesilate
108
daratumumab
95
fludarabine phosphate
69
carfilzomib
69
pomalidomide
68
Peripheral Blood Stem Cell Transplantation
64
Filgrastim
56
Thalidomide
55
Busulfan
53
Mycophenolic Acid
52
Tacrolimus
45
Granulocyte Colony-Stimulating Factor
45
ixazomib
43
fludarabine
42
Whole-Body Irradiation
40
Cyclosporine
35
Etoposide
33
dexamethasone acetate
31
Antilymphocyte Serum
31
isatuximab
29
dexamethasone 21-phosphate
26
Prednisone
26
elotuzumab
25
Biopsy
25
auricularum
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Multiple Myeloma
×
Vinorelbine
×
Clear all
NCT03442673
2025-03-28
MOCCCA
Insel Gruppe AG, University Hospital Bern
Phase 2
Completed
137 enrolled
NCT02791373
2018-04-03
ViGeM
Insel Gruppe AG, University Hospital Bern
Phase 2
Completed
136 enrolled
NCT01220375
2014-04-17
PAV
Insel Gruppe AG, University Hospital Bern
Phase 2
Completed
44 enrolled